For women with advanced breast cancer who have already tried the current generation of targeted treatments and seen their cancer progress anyway, options narrow sharply. The cancer has evolved a way around the drugs that were supposed to stop it. What comes next is usually harsher, less tolerable, and less effective.
Pfizer announced on March 18, 2026 that a new experimental drug — atirmociclib — has shown statistically significant and clinically meaningful improvement in progression-free survival in exactly this group of patients, in a Phase 2 clinical trial called FOURLIGHT-1.
What Atirmociclib Does
Breast cancer cells, like all cancer cells, need to copy their DNA and divide to grow. A family of proteins called CDK4 and CDK6 are crucial gatekeepers of this process. The current standard of care for hormone receptor-positive, HER2-negative advanced breast cancer — drugs like palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) — works by inhibiting both CDK4 and CDK6 together, slowing the cancer's ability to divide.
The problem is that cancers adapt. After a period of treatment, many tumours develop resistance mechanisms, particularly against CDK6 inhibition. When that happens, the standard drugs stop working.
Atirmociclib is designed differently. It is a selective CDK4 inhibitor — targeting CDK4 with far greater precision while leaving CDK6 largely alone. The hypothesis is that a CDK4-specific drug can still suppress the cancer even after it has become resistant to dual CDK4/6 inhibition, because it attacks the cell cycle through a different mechanism.
The Trial Results
The FOURLIGHT-1 Phase 2 trial enrolled patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had already received a CDK4/6 inhibitor and seen their cancer progress. These are precisely the patients for whom current options are most limited.
In combination with fulvestrant (a standard hormone-blocking therapy), atirmociclib demonstrated a statistically significant improvement in progression-free survival compared to fulvestrant alone. The safety profile was described as manageable and consistent with previous studies of the drug. Full data will be presented at a forthcoming medical conference.
Why This Matters
Hormone receptor-positive, HER2-negative breast cancer is the most common subtype of breast cancer — approximately 70% of all breast cancers. CDK4/6 inhibitors have transformed outcomes for these patients over the last decade. But CDK4/6 resistance is now one of the central challenges in breast oncology, affecting hundreds of thousands of patients globally each year.
If atirmociclib continues to show benefit in larger Phase 3 trials, it would represent a genuinely new treatment option for patients who currently face a difficult path after CDK4/6 resistance — extending the reach of targeted therapy into a space where few effective options currently exist.
Pfizer expects to move the drug into Phase 3 studies based on the FOURLIGHT-1 results.
Sources: Pfizer press release, March 18, 2026; EurekaAlert; ClinicalTrials.gov; American Cancer Society (breast cancer statistics)
